Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Long-Term Efficacy of Vedolizumab in Pediatric Inflammatory Bowel Disease
Selected as a Presidential Poster Harry E. Sarles - DHAT Research Institute, Richardson, TX Annette E. Whitney - Digestive Health Associates of Texas, Dallas, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen - Healix Infusion...
Use of Ustekinumab in Pediatric Crohn’s Disease – A Report of Three Cases
Harry E. Sarles - DHAT Research Institute, Richardson, TX Annette E. Whitney - Digestive Health Associates of Texas, Dallas, TX Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Thomas C....
Response and Healthcare Resource Utilization in Inflammatory Bowel Disease Patients Treated with Either Infliximab or Vedolizumab
Harry E. Sarles - DHAT Research Institute, Richardson, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX View...
Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
Quyen Luu - Central Georgia Infectious Diseases, Macon, GA H. Barry Baker - Infectious Disease Physicians, Miami, FL Ramesh V. Nathan - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA Richard L. Hengel - Atlanta ID Group, Atlanta, GA Alfred E. Bacon, III -...
Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
John S. Adams - Knoxville Infectious Disease Consultants, Knoxville, TN Brian S. Metzger - Austin Infectious Disease Consultants, Austin, TX Richard M. Mandel - Southern Arizona Infectious Disease Specialists, Tucson, AZ Thomas K. Sleweon - Infectious Disease...
Recurrent Clostridioides Difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
Kevin W. Garey - University of Houston College of Pharmacy, Houston, TX Claudia P. Schroeder - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land, TX Richard L. Hengel - Atlanta ID Group, Atlanta, GA Timothy E. Ritter -...
Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs)
Richard C. Prokesch - Infectious Disease Associates, Riverdale, GA Claudia P. Schroeder - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Infectious Disease Associates, Riverdale, GA Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX View...
Application of Bayesian Modeling with Infliximab to Determine Optimal Patient Specific Regimen
Authors: Timothy E. Ritter, MD – Texas Digestive Disease Consultants, Southlake, TX, U.S. Harry E. Sarles, MD – DHAT Research Institute, Garland, TX, U.S. Robert C. McLeay, PhD – DoseMeRx, Brisbane, Australia Lucinda J. Van Anglen, PharmD – Healix LLC, Sugar Land,...
Tolerability and Persistence with Subcutaneous Immunoglobulin Provided Through Physician Clinics for the Treatment of Primary Immunodeficiencies
Authors: Richard F. Herrscher, MD, FACAAI - AIRCare, Dallas, Texas Tidence L. Prince, MD - The Allergy Asthma and Sinus Center, Knoxville, TN Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion...
Failure of Vedolizumab as First Line Biologic Does Not Decrease Response Rate of Second Line Therapy
Authors: Timothy E. Ritter, MD - Texas Digestive Disease Consultants, PA, Southlake, TX Chris Fourment, MD - Texas Digestive Disease Consultants, PA, Southlake, TX Bitaal Sadiq, BS - Texas Digestive Disease Consultants, PA, Southlake, TX Claudia P. Schroeder,...
Therapeutic Drug Monitoring of Biologics in patients with Inflammatory Bowel Disease: A Real-World Experience
Authors: Chris Fourment, MD - Texas Digestive Disease Consultants, PA, Southlake, TX Timothy E. Ritter, MD, - Texas Digestive Disease Consultants, PA, Southlake, TX Bitaal Sadiq, BS - Texas Digestive Disease Consultants, PA, Southlake, TX Claudia P. Schroeder,...
Mandated Payor Switching with Infliximab (IFX) Bioimilars
Authors: Harry E. Sarles, MD, FACG - DHAT Research Institute, Richardson, TX Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX View...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.